Pernix Therapeutics Inc. to Report Second Quarter 2015 Financial Results on Thursday, August 6, 2015

MORRISTOWN, N.J., July 24, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that it will release its 2015 second quarter financial results on Thursday, August 6, 2015, before the market opens.

Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date:	Thursday, August 6, 2015
Time:	8:30 A.M. EDT
Toll free (U.S.)	877-312-8783
International	408-940-3874

The presentation will be webcast and available on the Investors section of the Company's website at http://www.pernixtx.com/investors/webcasts-presentations/. A replay of the webcast will be available for 30 days after the date of the presentation.

About Pernix Therapeutics

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

To learn more about Pernix Therapeutics, visit www.pernixtx.com.

CONTACT: Investor Relations
         Sanjay Patel, (800) 793-2145 ext. 1009
         Chief Financial Officer
         [email protected]

         Lisa Wilson, 212-452-2793
         In-Site Communications
         [email protected]

         Media Relations
         Marianne Lambertson, (800) 793-2145 ext. 1012
         Vice President, Marketing and Corporate Communications
         [email protected]

Source: Pernix Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• European stocks rise; Tesla earnings boost global sentiment
• Renasant Corp. (RNST) Tops Q1 EPS by 3c